Coronavirus SARS-CoV2: BESSY II data accelerate drug development

Schematic representation of the coronavirus protease. The enzyme comes as a dimer consisting of two identical molecules. A part of the dimer is shown in colour (green and purple), the other in grey. The small molecule in yellow binds to the active centre of the protease and could be used as blueprint for an inhibitor.

Schematic representation of the coronavirus protease. The enzyme comes as a dimer consisting of two identical molecules. A part of the dimer is shown in colour (green and purple), the other in grey. The small molecule in yellow binds to the active centre of the protease and could be used as blueprint for an inhibitor. © H. Tabermann/HZB

Filmclip: At BESSY II, the main protease of SARS-CoV2 has been decoded. This might help to develop drugs. © HG Medien/HZB

01:11

A coronavirus is keeping the world in suspense. SARS-CoV-2 is highly infectious and can cause severe pneumonia with respiratory distress (COVID-19). Scientists are doing research in order to prevent the viruses from multiplying. A team from the University of Lübeck and from Helmholtz Centre for Infection Research (HZI) has now found a promising approach. Using the high-intensity X-ray light from the Berlin synchrotron source BESSY II, they have decoded the three-dimensional architecture of the main protease of SARS-CoV-2. This protein is involved in the reproduction of the virus. Analysing its 3D architecture allows the systematic development of drugs which inhibit the reproduction of the virus.

Teams around the world are working hard to develop active substances against SARS-CoV-2. The structural analysis of functional proteins of the virus is very helpful for this goal. The function of a protein is closely related to its 3D architecture. If this 3D architecture is known, it is possible to identify specific points of attack for active substances.

Inhibiting the reproduction

A special protein is involved in the reproduction of the virus: the viral main protease (Mpro or also 3CLpro). A team led by Prof. Dr. Rolf Hilgenfeld, University of Lübeck, has now decoded the 3D architecture of the main protease of SARS-CoV-2. The researchers have used the high-intensity X-ray light from the BESSY II facility of the Helmholtz-Zentrum Berlin.

Fast track at BESSY II

"For such issues of highest relevance, we can offer fast track access to our instruments", says Dr. Manfred Weiss, who heads the Research Group Macromolecular Crystallography (MX) at HZB. At the so-called MX instruments tiny protein crystals can be analysed with highly brilliant X-ray light. The images contain information about the 3D architecture of the protein molecules. The complex shape of the protein molecule and its electron density is then calculated by computer algorithms.

Targets for active substances

The 3D architecture provides concrete starting points for developing active substances or inhibitors. These drugs could dock specifically to target points of the macromolecule and impede its function. Rolf Hilgenfeld is a world-renowned expert in the field of virology and already developed an inhibitor against the SARS-virus during the 2002/2003 SARS pandemic. In 2016, he succeeded in deciphering an enzyme of the Zika virus. 

 

Science, 20. March 2020: Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Linlin Zhang, Daizong Lin, Xinyuanyuan Sun, Ute Curth, Christian Drosten, Lucie Sauerhering, Stephan Becker, Katharina Rox, Rolf Hilgenfeld

DOI: 10.1126/science.abb3405 

arö


You might also be interested in

  • MXenes for energy storage: Chemical imaging more than just surface deep
    Science Highlight
    17.06.2024
    MXenes for energy storage: Chemical imaging more than just surface deep
    A new method in spectromicroscopy significantly improves the study of chemical reactions at the nanoscale, both on surfaces and inside layered materials. Scanning X-ray microscopy (SXM) at MAXYMUS beamline of BESSY II enables the investigation of chemical species adsorbed on the top layer (surface) or intercalated within the MXene electrode (bulk) with high chemical sensitivity. The method was developed by a HZB team led by Dr. Tristan Petit. The scientists demonstrated among others first SXM on MXene flakes, a material used as electrode in lithium-ion batteries.
  • New joint leadership for BESSY II
    News
    13.06.2024
    New joint leadership for BESSY II
    Andreas Jankowiak as new Technical Director and Facility Spokesperson Antje Vollmer share management responsibilities.

    Prof. Andreas Jankowiak has been appointed Technical Director of BESSY II with a term of office of three years as of 1 June 2024 by resolution of the HZB board of directors. Antje Vollmer will start her second term as BESSY II Facility Spokesperson on 1 July 2024. Together, they form the new management duo to coordinate the scientific and technical development of the BESSY II X-ray source on behalf of the HZB management.

  • Chilean President visits Helmholtz-Zentrum Berlin
    News
    12.06.2024
    Chilean President visits Helmholtz-Zentrum Berlin
    The President of Chile, Gabriel Boric Font, visited HZB on 11 June with a delegation of 50 people. Among the highlights of the evening were the signing of a Memorandum of Understanding between the Chilean Corporation for the Promotion of Production (CORFO) and HZB and a visit to BESSY II light source.